

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 80793

**Title:** Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02528485

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** Poland

**Manuscript submission date:** 2022-10-12

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-10-14 01:04

**Reviewer performed review:** 2022-10-17 07:26

**Review time:** 3 Days and 6 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous
	Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No

## SPECIFIC COMMENTS TO AUTHORS

In this article, the authors have reviewed the different treatments of hepatitis C and discussed the effect of Direct Acting Antivirals on the changing profile of hepatitis C patients. Several suggestions: 1. In [abstract], please check [Despite the excellent effectiveness of therapy HCV]. 2. In [introduction], lines 8-9, [hepatitis C virus] but not [hepatitis C] is suggested. 3. In [introduction], line 8, [direct acting antivirals] but not [direct drugs antivirals]. 4. In [Regimens without direct acting antivirals], the last paragraph, please check [Among the most common fatigue, headache, fever, malaise, myalgia, neutropenia and thrombocytopenia were reported]. 5. In [Genotype-specific options], the last paragraph, please check [nonvirologic nonresponders.]. 6. In [Pangenotypic options], the last paragraph, please add a reference after [was also registered for patients with compensated liver disease]. 7. In [SPECIFIC SUBPOPULATIONS OF HCV-INFECTED PATIENTS], please add a reference after [associated treatment discontinuation, and lower efficacy]. 8. In [Patients with compensated liver cirrhosis], please add a reference after [decompensated cirrhosis due to the side effects of this cytokine] and after [because of the risk of worsening liver function]. 9. In [conclusion], please mention at least one factor after [some factors are still identified that lower the chances of a cure].

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 80793

**Title:** Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05562744

**Position:** Editorial Board

**Academic degree:** FACS, MD, PhD

**Professional title:** Professor, Senior Scientist

**Reviewer's Country/Territory:** Turkey

**Author's Country/Territory:** Poland

**Manuscript submission date:** 2022-10-12

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-11-03 03:18

**Reviewer performed review:** 2022-11-08 17:57

**Review time:** 5 Days and 14 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: [ <input type="checkbox"/> ] Anonymous [ <input checked="" type="checkbox"/> ] Onymous
	Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors present a very good review regarding the antiviral agents in the treatment of HCV. I believe th manuscript is professionally written.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 80793

**Title:** Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02528485

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** Poland

**Manuscript submission date:** 2022-10-12

**Reviewer chosen by:** Han Zhang

**Reviewer accepted review:** 2022-12-16 00:38

**Reviewer performed review:** 2022-12-16 03:22

**Review time:** 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors have addressed the issues I have raised previously.